AJO International最新文献

{"title":"Assessment of intraocular pressure changes following intravitreal injections of three anti-VEGF agents","authors":"Amit Hibsh ,&nbsp;Adiel Barak ,&nbsp;Efrat Fleissig,&nbsp;Michael Regenbogen,&nbsp;Ainat Klein","doi":"10.1016/j.ajoint.2024.100001","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100001","url":null,"abstract":"<div><h3>Purpose</h3><p>Intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) agents has emerged as the primary treatment for prevalent retinal diseases. Despite its efficacy, IVI may induce intraocular pressure elevation due to vitreous fluid shifts. This study aims to compare the effects of three distinct anti-VEGF agents on intraocular pressure (IOP) elevation within a single clinic setting.</p></div><div><h3>Design</h3><p>A prospective study, conducted at a single retinal clinic in a tertiary medical center (Tel Aviv Sourasky Medical Centre, Tel-Aviv, Israel).</p></div><div><h3>Methods</h3><p>Patients receiving 3 different anti VEGF medications; bevacizumab, aflibercept, and ranibizumab, were examined. IOP was measured pre- and post-injection using an iCare Pro-tonometer. Demographic parameters and ocular characteristics were collected.</p></div><div><h3>Results</h3><p>The study included 195 patients (average age 76.13 years; 100 males, 95 females). The medications administered were aflibercept (<em>N</em> = 70, 35 %), bevacizumab (<em>N</em> = 73, 37.4 %), and ranibizumab (<em>N</em> = 52, 26.7 %). In patients with a normal baseline intraocular pressure, no significant variance was observed in the post-injection versus pre-injection pressure change (delta) across medications. Conversely, in patients with higher pressure (&gt;20 mmHg), aflibercept incited a more substantial increase than bevacizumab or ranibizumab. No correlation emerged between the pressure rise and age or lens status.</p></div><div><h3>Conclusions</h3><p>No significant difference was found in the increase of intraocular pressure following injection among different medications in patients with low-normal intraocular pressure. However, for patients prone to higher baseline pressure, caution is recommended with aflibercept due to a more pronounced increase. Further research is essential to comprehend the factors influencing pressure increase and their associated clinical implications.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 1","pages":"Article 100001"},"PeriodicalIF":0.0,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000017/pdfft?md5=2343bc89648f5d4b5dcf748054bd865c&pid=1-s2.0-S2950253524000017-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140191278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A global survey of visual symptoms in female carriers of choroideremia and X-linked retinitis pigmentosa","authors":"Sena A Gocuk ,&nbsp;Thomas L Edwards ,&nbsp;Jasleen K Jolly ,&nbsp;Lauren N Ayton","doi":"10.1016/j.ajoint.2024.100002","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100002","url":null,"abstract":"<div><h3>Purpose</h3><p>To investigate self-reported visual impairment in a large cohort of female carriers of X-linked retinal diseases around the world, using the validated Michigan Retinal Degeneration Questionnaire (MRDQ).</p></div><div><h3>Design</h3><p>Cross-sectional global survey study</p></div><div><h3>Methods</h3><p>An online survey collecting demographic and MRDQ data was distributed to self-reported female carriers of X-linked retinal diseases, and healthy controls (females with no eye disease). Respondents indicated their visual symptoms relating to everyday activities in seven visual domains: central vision, colour vision, contrast sensitivity, scotopic function, photopic peripheral vision, mesopic peripheral vision, and photosensitivity. Mann-Whitney test was used to compared visual disability scores between female carriers and healthy controls.</p></div><div><h3>Results</h3><p>Two-hundred and thirty-seven female carriers of X-linked retinal diseases (74.3% choroideremia and 25.7% X-linked retinitis pigmentosa) and 100 age-matched healthy controls completed the questionnaire (median age: 51 vs. 47.5 years of age, respectively). Most female carriers resided in the USA (53.6%) and Australia (17.3%), whilst healthy controls were mostly from Australia (93%). Female carriers had significantly worse visual disability, compared to controls. Female carriers who were older than 50 years had significantly worse visual function impairment for all domains, except photosensitivity, when compared to carriers less than 50 years of age.</p></div><div><h3>Conclusions</h3><p>This study has shown that female carriers of choroideremia and X-linked RP report significantly worse visual symptoms, compared to healthy controls. Future studies are required to correlate MRDQ responses with clinical findings, to determine the degree of retinal changes required to impact female carriers’ quality of life.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 1","pages":"Article 100002"},"PeriodicalIF":0.0,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000029/pdfft?md5=7f286e8c785d5717b21e2a05bfc07087&pid=1-s2.0-S2950253524000029-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights on Mesenchymal to Epithelial Transition (MET) for fibrosis reversal in ocular tissue","authors":"Sarbani Hazra","doi":"10.1016/j.ajoint.2024.100003","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100003","url":null,"abstract":"","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 1","pages":"Article 100003"},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000030/pdfft?md5=06223532ddd3bcf9f081603821bcc7f4&pid=1-s2.0-S2950253524000030-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}